Sumitomo Mitsui Trust Group
CTMX icon

Sumitomo Mitsui Trust Group’s CytomX Therapeutics CTMX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-49,600
Closed -$380K – 1108
2020
Q1 		$380K Buy
+49,600
New +$346K ﹤0.01% 1024

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sumitomo Mitsui Trust Group's CTMX Position: Q2 2020 in Review

Sumitomo Mitsui Trust Group sold out of CytomX Therapeutics (CTMX) in Q2 2020, closing a stake of 49,600 shares — an estimated $380K sold.

Sumitomo Mitsui Trust Group first reported a position in CTMX in Q1 2020 and held it in 1 quarter. The position peaked at $380K in Q1 2020. 134 funds tracked by Wall St. Rank hold CTMX as of Q2 2020.

  • Sumitomo Mitsui Trust Group reported no remaining CytomX Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 49,600 CytomX Therapeutics shares in Q2 2020, an estimated $380K.
  • Sumitomo Mitsui Trust Group first reported a position in CytomX Therapeutics in Q1 2020 and held it in 1 quarter.
  • Sumitomo Mitsui Trust Group's CytomX Therapeutics position peaked at $380K in Q1 2020.
  • 134 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2020.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2020, filed 27 Jul 2020.